Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7507
Abstract: 7507Background: Pola is an antibody-drug conjugate targeting CD79b+ cells in B-NHL. Early results led to FDA breakthrough therapy status and EMA PRIME designation. We now report combined results fo... read more here.
Keywords: vedotin pola; randomized phase; pola bendamustine; trial polatuzumab ... See more keywords